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Abstract: Polyethylene glycol (PEG) has been successfully used for improving circulation time of
several nanomaterials but prolonging the circulation of porous silicon nanoparticles (PSi NPs)
has remained challenging. Here, we report a site specific radiolabeling of dual-PEGylated
thermally oxidized porous silicon (DPEG-TOPSi) NPs and investigation of influence of the
PEGylation on blood circulation time of TOPSi NPs. Trans-cyclooctene conjugated DPEG-TOPSi
NPs were radiolabeled through a click reaction with [111In]In-DOTA-PEG4-tetrazine (DOTA =
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) and the particle behavior was evaluated
in vivo in Balb/c mice bearing 4T1 murine breast cancer allografts. The dual-PEGylation significantly
prolonged circulation of [111In]In-DPEG-TOPSi particles when compared to non-PEGylated control
particles, yielding 10.8 ± 1.7% of the injected activity/g in blood at 15 min for [111In]In-DPEG-TOPSi
NPs. The improved circulation time will be beneficial for the accumulation of targeted DPEG-TOPSi
to tumors.
Keywords: SPECT; indium-111; click chemistry; porous silicon; IEDDA
1. Introduction
Several different types of nanomaterials have been investigated as carriers for targeted delivery of
therapeutic and diagnostic agents in cancer [1]. For targeted delivery, the surface of the nanocarrier is
functionalized with affinity ligands such as tumor receptor binding peptides or antibody fragments [2].
For efficient recognition and retention, the carrier needs to exhibit sufficient circulation time to enable
the targeting ligand to interact with the tumor cells. Unfortunately, the human body has efficient
clearance mechanisms which influence the circulation time of nanoparticles (NPs) and can still make
the targeted delivery with nanocarriers a challenge. The circulation time has been found to be affected
by several factors, such as size, morphology, and surface chemistry of the carrier. The NPs with
size beyond 100 nm are rapidly and efficiently uptaken by the liver and the spleen to so-called
reticuloendothelial system (RES) [3]. Spherical and discoidal shape has been found to be preferable
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and engineered surface coating can further improve the residence time in circulation. The surface
coating affects circulation time by delaying and preventing the opsonization process [4–6].
Porous silicon nanoparticles (PSi NPs) are considered as a good option for biomedical applications
due to their biocompatibility and favorable physiochemical properties such as tunable particle and
pore size, adjustable surface chemistry, and high degree of porosity [7,8]. The nontoxic biodegradation
of PSi NPs in vivo into silicic acid and possibility to influence its biodegradation rate with surface and
porosity modifications makes PSi NPs a suitable material for biological applications [9–12]. Despite
of the recent successful delivery of therapeutics by multifunctional PSi NPs [13,14], there have been
only a few reports for the prolongation of the NPs resident time in blood stream for intravenously
administered PSi nanoparticles [15,16]. Consequently, without the improvements in the residence
time in circulation, the NPs delivery to the target remains a challenge [17]. Polyethylene glycol
(PEG) is widely used surface coating for improving the stealth properties of NPs, however, it has
exhibited limited effect in increasing the circulation residence time of PSi nanoparticles [18]. It has
been reported that the molecular weight of the PEG chain and the grafting density can enhance the
stealth properties of PSi NPs [19]. A dense and thick PEG coating should improve the circulation time
for example by slowing the nanoparticle phagocytosis by macrophages and by reducing non-specific
protein absorption and aggregation [20]. Indeed, dualPEGylation of PSi surface by simultaneous
conjugation with 0.5 kDa and 2 kDa PEG chains has been reported to prevent opsonization in vivo [15].
In cancer research, nanoparticles have demonstrated passive tumor targeting due to the enhanced
permeation and retention effect (EPR) [21]. The EPR effect is a typical feature of tumors and related
to their anatomical and pathophysiological differences from normal tissues [22]. Changes in tumor
vasculature result in increased extravasation of nanoparticles from the blood to the tumor tissue [23].
Small size (<200 nm) as well the shape of the nanoparticle will significantly affect its potential for
passive targeting [24].
Click chemistry has been widely studied in the radiopharmaceutical field because it is easily
customized to different purposes [25,26]. Common for all click reactions are their fast reaction
kinetics in very low concentrations and in aqueous media at room temperature which allows for
use in a multitude of applications [27]. Click chemistry enables the site-specific radiolabeling of
nanomaterials. Amongst all click reactions in cancer imaging and material science, the most efficient
reaction reported is the [4 + 2] cycloaddition of 1,2,4,5-tetrazines and various dienophiles, known
as the inverse electron-demand Diels–Alder (IEDDA) reaction, exhibiting the fast reaction kinetics,
selectivity, and biocompatibility [28,29]. Each dienophile used in IEDDA has their pros and cons; for
example, trans-cyclooctene (TCO) displays the fastest reaction kinetics but transforms relatively fast to
its non-reactive cis form while bicyclo[6.1.0]nonyne (BCN) is more stable but the reaction kinetics are
slower than compared to TCO [30–32].
The aim of this project was to investigate the optimal radiolabeling method for dual-PEGylated
mesoporous silicon nanoparticles (DPEG-TOPSi) and to evaluate their blood circulation time
and tumor accumulation in 4T1 murine breast cancer allografts. Several different labeling
strategies were tested during the process, including a direct 111In-radiolabeling of DOTA
(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) conjugated DPEG-TOPSi NPs and a click
chemistry approach with [111In]In-DOTA-PEG4-Tz for radiolabeling of either bicyclo[6.1.0]nonyne
(BCN) or trans-cyclooctene (TCO) conjugated DPEG-TOPSi NPs. The in vitro stability of the
radiolabeled NPs was studied to ensure good radiolabel stability and for selecting the most stable
radiolabeling strategy for the in vivo evaluation. The effect of PEGylation on the circulation half-life and
tumor accumulation of NPs was studied with 4T1 tumor-bearing Balb/c mice with [111In]In-DPEG-TOPSi
particles and the non-PEGylated control particles ([111In]In-TOPSi) by using SPECT/CT and ex vivo
biodistribution studies.
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2. Materials and Methods
2.1. Materials and Chemicals
All chemicals and solvents were obtained from commercial providers and they were used without
further purification. N-(4-(1,2,4,5-tetrazin-3-yl)benzyl)-1-amino-3,6,9,12-tetraoxapentadecan-15-amide
(Tz-PEG4-NH2) was purchased from Conju-Probe (San Diego, CA, U.S.A.) and
2,2′,2”-(10-(2-(2,5-dioxopyrrolidin-1-yl)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic
acid (DOTA-NHS ester) from Macrocyclics. (1R,8S,9S)-Bicyclo[6.1.0]non-4-yn-9-ylmethyl
N-succinimidyl carbonate (BCN-NHS) was purchased from Sigma-Aldrich (St. Louis, MO,
U.S.A.) and trans-Cyclooctene-PEG4-NHS ester (TCO-NHS) from Jena Bioscience (Jena, Germany).
Silicon wafers (p+-type, resistivity 0.007–0.02 Ωcm) were received from Okmetic Oyj (Vantaa, Finland).
Dimethyl sulfoxide (DMSO), 2-propanol (IPA), fetal bovine serum (FBS), Tween® 20, triethylamine
(TEA), [3-(2-Aminoethylamino)propyl]trimethoxysilane (AEPTMS), and L-glutamine were purchased
from Sigma-Aldrich. Phosphate buffered saline (PBS) and penicillin/streptomycin (P/S) were obtained
from HyClone (Logan, UT, U.S.A.). Dulbecco’s Modified Eagle Medium (DMEM) was obtained
from Biowest (Nuaillé, France). The 2 kDa mPEG-silane and 0.5 kDa mPEG-silane were purchased
from Huateng Pharma (Changsha, China) and Fluorochem (Derbyshire, UK) respectively. Trypsin
was purchased from Thermo Fisher Scientific (Waltham, MA, U.S.A.). Ultrapure water (18.2 MΩ)
was prepared on a Milli-Q Integral 10 water purification system. [111In]InCl3 was purchased from
Mallinckrodt Medical B.V. (Petten, The Netherlands).
2.2. Methods
2.2.1. Preparation of BCN and TCO Conjugated Nanoparticles
DPEG-TOPSi NPs were prepared as described previously from single-crystal p+-type Si wafers
and were anodized in 1:1 (v/v) 38% hydrofluoric acid and ethanol solution with the pulse sequences [33].
Briefly, PSi NPs were oxidized at 300 ◦C for 2 h in ambient air to produce TOPSi and further chemically
oxidized to increase the surface density of hydroxyl groups (TOPSi-OH) [34]. Mixture of 0.5-kDa
and 2-kDa PEG was dissolved in anhydrous toluene, after which TOPSi-OH NPs was added to the
solution [34,35]. The dispersion was heated overnight (~18 h) at 110 ◦C under reflux. At the end of the
process, the reaction solvent was evaporated and the PEGylated PSi NPs were dispersed in ethanol.
The PEGylated TOPSi (DPEG-TOPSi) NPs were rinsed with ethanol twice and 5–10 min sonication
was applied during each rinsing to remove any physically adsorbed PEG. Amine groups were added
to the surface of the nanoparticles (DPEG-TOPSi-NH2) for conjugation with the dienophiles. Briefly,
DPEG-TOPSi NPs (20 mg) were dispersed in ethanol (2 mL) with AEPTMS (5 µL) and incubated for
2 h under constant rotation. Prepared DPEG-TOPSi-NH2 NPs were rinsed twice with ethanol and
were dispersed in DMSO (5 mg/mL) and TEA (50 µL) with equal amount of BCN-NHS or TCO-NHS
and incubated overnight under constant rotation. The non-PEGylated TOPSi NPs were functionalized
with the same conjugation chemistry.
2.2.2. Synthesis of 2,2′,2”-(10-(18-((4-(1,2,4,5-tetrazin-3-yl)phenyl)amino)-2,18-dioxo-6,9,12,15-tetraoxa-
3-azaoctadecyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid (1, DOTA-PEG4-Tz)
Tz-PEG4-NH2 (25.4 µmol) and DOTA-NHS ester (24.0 µmol) were diluted to 2 mL
dimethylformamide (DMF) and 100 µL TEA (716.0 µmol) was added to the reaction mixture and
the mixture was stirred overnight at room temperature. Reaction was monitored by TLC (silica,
DCM:MeOH, 10:1, Rf(1) = 0.75). The product was purified by semi-preparative HPLC (Waters
Symmetry Prep™ C18, eluent: 0.1% TFA in water/ACN, ACN gradient 10% to 80%, 3 mL/min, UV
detection at 270 nm, Rt(1) = 9.26 min), and evaporated to dryness, yielding a red oil. Final compound
was analyzed with 1H-NMR (Varian Mercury 300 MHz, CD3OD): δ 10.33 (s, 1H), 8.57 (d, 2H), 7.60 (d,
2H), 4.54 (s, 2H), 3.92 (br, 3H), 3.80 (m, 12H), 3.64 (s, 6H), 3.60 (m, 18H), 3.35 (s, 2H) and 2.58 (t, 4H)
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and TOF-ESI-MS mass spectrometry (Bruker Daltonics micrOTOF). Negative ionization mode used in
measurement, m/z calc. 819.4079 for C36H54N10O12−, found 819.3996.
2.2.3. Conjugation of 1 to BCN-DPEG-TOPSi
BCN-DPEG-TOPSi particles (0.5–2 mg) were washed twice with PBS, followed by repeated
centrifugations (5 min, 12,000 rpm). Particles were dispersed to PBS (pH = 7.4) and sonicated with a
tip sonicator (QSonica, Newtown, CT, U.S.A) at 20% amplitude for 10 s. DOTA-PEG4-Tz (1, 0.6–1.2 mg,
0.73–1.46 µmol) in PBS (pH = 7.4, 200 µL) was added to the reaction mixture and the mixture was
incubated in room temperature overnight. The conjugated particles were purified with repeated
centrifugations in PBS (5 min, 12,000 rpm).
2.2.4. Conjugation of 1 to TCO-DPEG-TOPSi
TCO functionalized DPEG-TOPSi particles were conjugated with DOTA-PEG4-Tz (1, 0.5–1.0 mg,
0.61–1.22 µmol) by incubating the particles (0.1–1.0 mg) in PBS in room temperature overnight. The
conjugated particles were purified with repeated centrifugations in PBS (5 min, 12,000 rpm).
2.2.5. 111In-radiolabeling of DPEG-TOPSi Particles
Approach A: The DOTA-PEG4-Tz (1) conjugated BCN or TCO functionalized particles were
labeled with [111In]InCl3 (2–10 MBq) in 0.2 M NH4OAc buffer (100–500 µL, pH = 6.8, 37 ◦C) at 30 min
with constant shaking followed by purification of repeated centrifugations with PBS (pH = 7.4), EtOH
and PBS (5 min, 12,000 rpm). Radiochemical purity of the radiolabeled particles was controlled with
i-TLC-SA (50 mmol EDTA in 0.9% NaCl) and was >98% for both particle types. Particle size for
the radiolabeled particles was measured with Zetasizer Nano ZS (Malvern, Worcestershire, UK) in
PBS solution.
Approach B: DOTA-PEG4-Tz (1, 0.01–0.0001 mg, 0.12–12.2 nmol) was mixed in a conical centrifuge
tube with 0.2 M NH4OAc buffer (100–500 µL, pH = 6.8) and [111In]InCl3 (2–50 MBq). The mixture was
stirred gently for 10 min at 37 ◦C and purified by solid phase extraction (Sep-Pak light C-18, Waters
Corporation, Milford, Massachusetts, U.S.A.). The C18 cartridge was pretreated with 2 mL of EtOH
and 10 mL of mQ-H2O. The reaction mixture was loaded to the cartridge, washed with 10 mL mQ-H2O
and the product, [111In]In-DOTA-PEG4-Tz ([111In]1) eluted with 20% EtOH in mQ-H2O solution. The
DPEG-TOPSi and TOPSi particles, which were functionalized either with TCO or BCN, were labeled
with [111In]In-DOTA-PEG4-Tz ([111In]1) for 30 min at 37 ◦C with constant shaking and purified by
repeated centrifugations with PBS (pH = 7.4), EtOH and PBS (5 min, 12,000 rpm). The radiochemical
purity of the radiolabeled particles was determined with i-TLC-SA (50 mmol EDTA in 0.9% NaCl) and
was >98% for the all particle types. Particle size for the radiolabeled particles was measured with
Zetasizer Nano ZS (Malvern, Worcestershire, UK) in PBS solution.
2.2.6. Particle Physicochemical Characterization
The size and ζ-potential of the nanoparticles were measured in water and the colloidal stability
in PBS was determined with dynamic light scattering (Malvern, Nano ZS Zetasizer, Worcestershire,
UK). Furthermore, the NP size and morphology were studied with transmission electron microscopy
(TEM, Jeol JEM 2100F, Tokio, Japan) after drying a droplet of the NP suspension onto a copper
grid and imaging with 200 kV beam. Chemical modifications were corroborated with transmittance
Fourier-transform infrared spectroscopy (FTIR, Thermo Nicolet 8700, Cheshire, UK) and the organic
content was determined with thermogravimetric analysis (TGA, TA Instruments TG Q50) by applying
the heating rate of 20 ◦C/min up to 800 ◦C at N2 atmosphere. N2 sorption (Micromeritics TriStar II 3020,
Norcross, GA, U.S.A.) at −196 ◦C was used for measuring the pore characteristics. Specific surface
areas were calculated using the Brunauer–Emmet–Teller (BET) method, and Barrett–Joyner–Halenda
(BJH) theory was used to obtain the pore size distributions.
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2.2.7. Cytotoxicity
The cytotoxicity of the nanoparticles with RAW 264.7 macrophages was evaluated. Briefly, the
cells were cultured in DMEM supplemented with 10% FBS, 1% P/S and 1% L-glutamine. The cells
(10,000/cm2) were plated on a 96-well plate and NPs (25, 50, 100 and 250 µg/mL) were incubated with
the cells for 24 h. The cells were rinsed twice with PBS before applying the CellTiter-Glo assay reagent.
The untreated cells and the cells incubated with 10% Tween® 20 were used as the negative and positive
controls, respectively. Luminescence was measured (PerkinElmer Victor 3, Waltham, MA, U.S.A.) to
determine the cell viability. The results are normalized to untreated cells (100%) and to Tween® 20
treated cells (0%).
2.2.8. Radiochemical Stability of the 111In-Labeled Particles
The in vitro stability of the [111In]In-DPEG-TOPSi and [111In]In-TOPSi particles, prepared by both
approaches (A and B), were investigated in PBS (pH = 7.4) and in human plasma (10% and 50%).
For the stability tests, freshly prepared [111In]In-DPEG-TOPSi and [111In]In-TOPSi particles (0.5 mg,
1–3 MBq) were added to 1 mL of PBS or plasma solution in a protein LoBind microtube (Eppendorf)
and incubated at 37 ◦C under constant shaking. At the predetermined time points (1 h, 2 h and 5 h) the
nanoparticles were collected by centrifugation and the radioactivity of the pellet and supernatant were
measured by a dose calibrator (VDC-405, Veenstra Instruments, Castel Bolognese, Italy). All assays
were carried out in triplicate.
2.2.9. Ex Vivo Biodistribution
All animal experiments were carried out under a project license approved by the National Board
of Animal Experimentation in Finland (ESAVI/12132/04.10.07/2017, approved on 1 February 2018) and
in compliance with the respective institutional, national and EU regulations and guidelines. Mice were
group-housed in standard polycarbonate cages with aspen bedding and with food (Harlan) and tap
water available ad libitum. Environmental conditions of a 12:12 light/dark cycle, temperature of 22 ± 1
◦C, and relative humidity of 55 ± 15% were maintained throughout the study.
The ex vivo biodistribution studies were carried out in healthy (DOTA-PEG4-Tz, [111In]1, and
[111In]In-TOPSi control particles,) and 4T1 tumor-bearing Balb/c female mice ([111In]In-DPEG-TOPSi)
purchased from Charles River, aged 8–10 weeks, weighing 17–22 g (total n = 36). For 4T1 tumor-bearing
mice, 1 × 106 4T1 cells in 50 µl of additive-free RPMI-1640 medium were inoculated to the right
inguinal mammary fat pad under 2.5% isoflurane anesthesia in medical air:oxygen carrier (3:2,
1 L/min). In addition, local anesthesia infiltrated at the incision site (100 µL of 1:1 mixture of 5
mg/mL bupivacaine and 10 mg/mL lidocaine). Mice received carprofen 5 mg/kg (Norocarp, 50 mg/mL,
Norbrook Laboratories Ltd.) subcutaneously before the surgery and at 24 h and 48 h after the surgery.
Tumors were allowed to growth for 8–11 days before the administration of the radiolabeled NPs.
[111In]In-DPEG-TOPSi (100 µg) in 200 µL PBS (pH = 7.4) and the control particles, [111In]In-TOPSi
(100 µg) in 200 µL PBS-5% Solutol HS 15, were administered intravenously to the tail vein. The mice
were sacrificed at the predetermined time points by CO2 asphyxiation followed by cervical dislocation.
Tissues were collected at 5 min, 1 h, 4 h, 24 h, and 48 h time points for [111In]In-DPEG-TOPSi particles
and for [111In]In-TOPSi particles at 30 min and 1 h time points (n = 4 at each time point). The circulation
half-life of the particles was determined from venous blood samples by collecting a droplet from
the tail vein with a needle at 5 min, 15 min, and 30 min after administration for both particles. The
collected tissue samples were weighted individually, and their radioactivity measured by using a
gamma counter (Perkin Elmer Life Sciences, Waltham, MA, U.S.A.).
2.2.10. In Vivo SPECT/CT Imaging
4T1 tumor-bearing mice (n = 4) were intravenously injected with [111In]In-DPEG-TOPSi (2–4 MBq,
100 µg in 200 µL PBS, pH = 7.4) and scanned with a dedicated small animal SPECT/CT scanner (Bioscan
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NanoSPECT/CT, Mediso, Budapest, Hungary) at 1 h (dynamic scan), 5 h (static scan), and 24 h (static
scan) after the administration of the radiolabeled NPs. The SPECT/CT scans were carried out under
1.5–2.5% isoflurane anesthesia in oxygen carrier. The images were analyzed with VivoQuant program
(InviCRO LLC, Arlington, VA, U.S.A).
2.2.11. Autoradiography
Tumors harvested at the 1 h, 4 h, and 24 h time points after the intravenous injection of
[111In]In-DPEG-TOPSi particles were snap frozen in dry ice cold isopentane and embedded in tissue
freezing medium before sectioned with a cryostat microtome (Leica CM1950, Leica Biosystems, Wetzlar,
Germany) to 10 µm thick sections and collected to a glass slide (SuperFrost Plus, VWR). The sections
were scanned with a real-time digital autoradiography ai4r BeaQuant system (Nantes, France) for
24 h [36]. Same tumor sections were subsequently stained with hematoxylin–eosin (H&E) and scanned
at the Finnish Centre for Laboratory Animal Pathology (FCLAP).
3. Results and Discussion
3.1. Preparation of the DPEG-TOPSi Nanoparticles
In order to improve the stealth properties of PSi NPs, we decided to employ a dual-PEGylation
strategy, aiming to enhance masking of the surface against immunorecognition. Additionally, the dense
PEG layer could stabilize the TOPSi particles from enzymatic hydrolysis, which has been previously
observed for the thermally oxidized PSi and reported by us and other groups [37,38]. The irregularly
elongated shape of the TOPSi nanoparticle was not affected by the surface modifications as observed
with TEM (Figure 1A–C). However, after the dual-PEGylation the particles were more separated
instead of being as particle clusters because dual-PEGylation improved their dispersion. The success of
the chemical modifications were verified with FTIR (Figure 1D). In the spectrum of DPEG-TOPSi, the
1355 cm−1 and 1460 cm−1 emerges from the –CH3 and –CH2 bendings, respectively. The peaks at 1560,
1630, 1655, and 1725 cm−1 are from amide II bond, –O–H, amide I bond, –C=O stretching, respectively.
There is an amide bond in the 2.0 kDa PEG-silane and thus the amides and –C=O group were observed
in the spectrum of the DPEG-TOPSi [34]. The peak at 870 cm−1 in DPEG-TOPSi-NH2 was denoted
to be due to the N–H wag indicating the successful surface modification on the DPEG-TOPSi-NH2
NPs. The amount of the added organic molecules was studied with TGA (Figure 1E). The weight
losses for TOPSi, DPEG-TOPSi, and DPEG-TOPSi-NH2 were 3.3 ± 0.2 wt %, 21.0 ± 0.9 wt % and
21.7 ± 1.4 wt %, respectively. Thus, the DPEG and –NH2 content were 17.7 wt % and 0.7 wt %,
respectively. The pore characteristics were studied with N2-sorption (Figure 1F). All the samples
displayed the hysteresis effect that is typical for mesoporous materials. The dual-PEGylation decreased
the surface area and the pore volume (Table 1) as similarly observed previously by Nissinen et al.
(2016) [15]. The enhanced colloidal stability was studied by incubation the NPs in PBS (Figure 1G).
The dual-PEGylation improved significantly colloidal stability of the suspension; TOPSi aggregated
readily, but the DPEG-TOPSi was stable during the experiment. The amine addition in the sample
of DPEG-TOPSi-NH2 did not cause significant effect on its colloidal stability within 24 h. Finally,
the NP biocompatibility was confirmed after interaction with the RAW macrophages. No significant
differences were observed in any of the samples compared to the control (untreated cells).
Pharmaceutics 2019, 11, 686 7 of 16
Pharmaceutics 2019, 11, x 7 of 16 
 
 
Figure 1. Characterization of the nanoparticles: (A–C) TEM images of TOPSi, DPEG-TOPSi, and 
DPEG-TOPSi-NH2 NPs, (D–F) FT-IR spectra, TGA, and N2 ad/desorption curves (TOPSi (Blue), 
DPEG-TOPSi (Red) and DPEG-TOPSi-NH2 (Green)), (G) Colloidal stability of the nanoparticles in 
PBS at 37 °C at different time points, and (H) Viability of macrophages when incubated with different 
nanoparticles. 
Table 1. The size, polydispersity index (PDI), zeta potential, and N2 adsorption results of the porous 
silicon nanoparticles. 
Measure TOPSi TCO-
TOPSi 
[111In]In-
TOPSi 
DPEG-
TOPSi 
DPEG-
TOPSi-
NH2 
TCO-
DPEG-
TOPSi 
[111In]In-
DPEG-
TOPSi 
Size 
(diameter, 
nm) 
176 ± 6 225 ± 10 198 ± 4 192 ± 1 196 ± 4 276 ± 4 226 ± 3 
PDI 
0.06 ± 
0.03   
0.05 ± 
0.02 0.04 ± 0.02   
Figure 1. Characterization of the nanoparticl ( –C) TEM images of TOPSi, DPEG-TOPSi, and
DPEG-TOPSi-NH2 NPs, (D–F) FT-IR spectr , and N2 a /desorption curves (TOPSi (Blue),
DPEG-TOPSi (Red) and DPEG-TOPSi- 2 (Green)), (G) Colloidal stability of the nanoparticles
in PBS at 37 ◦C at different time points, and (H) Viability of macrophages when incubated with
different nanoparticles.
Table 1. The size, polydispersity index (PDI), zet t tial, and N2 adsorption results of the porous
silicon nanoparticles.
Measure TOPSi -TOPSi [
111In]In-
TOPSi
DPEG-
TOPSi
DPEG-TOPSi
-NH2
TCO-DPEG
-TOPSi
[111In]In-DPEG
-TOPSi
Size (diameter, nm) 176 ± 6 225 ± 10 198 ± 4 192 ± 1 196 ± 4 276 ± 4 226 ± 3
PDI 0.06 ± 0.03 0.05 ± 0.02 0.04 ± 0.02
Zeta potential (mV) −29.3 ± 0.9 −7.2 ± 0.2 12.0 0.8
BET surface area
(m2/g) 163 ± 20 60 ± 2 52 ± 9
BJH volume (m3/g) 0.48 ± 0.04 0.26 ± 0.02 0.27 ± 0.03
BJH pore size (nm) 9.8 ± 0.3 8.8 ± 0.8 10.4 ± 1.5
Pharmaceutics 2019, 11, 686 8 of 16
3.2. Radiolabeling of [111In]In-DPEG-TOPSi and [111In]In-TOPSi
Previously we have reported biological evaluation of several 111In-labeled PSi NPs [39,40].
Regardless of the surface chemistry, the particles have exhibited limited in vivo stability resulting to
some released 111In species and complicating quantification of the NP biodistribution at later time
points. Compromised radiochemical stability is a significant disadvantage especially when considering
the use of long circulating NPs, because making difference between the NP-bound and plasma protein
bound radiolabel is extremely difficult. Therefore we decided to investigate two different approaches
for radiolabeling of the TOPSi NPs, one with a one-step radiolabeling of the NPs in which the NPs
were functionalized with the 111In chelating DOTA-PEG4-Tz (1) prior to the labeling (Approach A) and
another in which the [111In]In-DOTA-PEG4-Tz ([111In]1) was first synthesized and then conjugated to
the NPs using the inverse electron-demand Diels-Alder click chemistry (Approach B) (Scheme 1).
The labelling precursor DOTA-PEG4-Tz (1) was successfully synthesized through an amide
coupling reaction between a DOTA-NHS ester and Tz-PEG4-NH2 with 78 ± 2% yield (n = 3) (Scheme 2
and Figure S4). In approach A, BCN- or TCO-functionalized DPEG-TOPSi particles were conjugated
first with DOTA-PEG4-Tz (1) and after removal of the unreacted DOTA-PEG4-Tz, [111In]InCl3 was used
for labeling. The one-step 111In-labeling approach A gave high labeling radiochemical yields (50 ± 11%),
regardless of the original BCN or TCO functionalization. In approach B, [111In]In-DOTA-PEG4-Tz
([111In]1) was first synthesized. Radiochemical yield of [111In]1 was >99% when at least 8 µg
(9.75 nmol) of precursor 1 was used (Scheme 2). The synthesized [111In]1 was conjugated to BCN-
and TCO-functionalized DPEG-TOPSi NPs through the IEDDA reaction in PBS (pH = 7.4) with
radiochemical yields of 13 ± 3% (n = 4) and 40 ± 8% (n = 4), respectively. Due to the significantly
higher radiochemical yields, we decided to continue our experiments with the TCO-functionalized
NPs. The control particles, TCO-TOPSi NPs were radiolabeled with approach B within a slightly better
radiochemical yield 52 ± 7% (n = 3). Particle size for the radiolabeled [111In]In-DPEG-TOPSi and
[111In]In-TOPSi particles (approach B) were measured and the hydrodynamic diameter were 226 ± 3
nm and 198 ± 4 nm, respectively.
Radiochemical stability for radiolabeled particles was determined by incubating the particles in
PBS (pH = 7.4) and in 10% and 50% human plasma. The results revealed that those DPEG-TOPSi
particles, which were radiolabeled with the one-step approach A, exhibited major loss of activity already
after 1 h in 10% plasma, while particles radiolabeled with the two-step approach B, demonstrated
excellent stability in PBS (pH = 7.4) and even at 50% plasma (82% after 5 h in 50% plasma) (Figure 2 and
Figure S1). The possible explanation for the observed difference is most probably a weak coordination
of the 111In3+ cation onto the oxidized surface and inside the pores. Obviously, we were not able to
completely remove the weak coordination despite of the careful and repeated washings. When exposed
to plasma the weakly bound trivalent radiometals can be transchelated with metal complexing proteins
such as transferrin [41]. When using the approach B, the free 111In3+ cation is not in a direct contact
with the oxidized surface, instead the trivalent radiometal is introduced to the particles complexed
with DOTA. The [111In]In-DOTA complex has been reported excellent thermodynamic stability for the
complex in vivo and supported also by our in vitro findings [42]. Due to their better in vitro stability
the NPs radiolabeled by approach B were selected for the in vivo evaluation.
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Figure 2. In vitro stability of [111In]In-DPEG-TOPSi and [111In]In-TOPSi particles in 10% and 50%
human plasma and 1 × PBS (n = 3). Comparison of radiolabel stability after radiolabeling the NPs
with two different methods; either by using the one-step approach A in which the NPs were incubated
with [111In]InCl3 or by the two-step approach B, in which the TCO-functionalized DPEG-PSi NPs were
radiolabeled by using a presynthesized [111In]In-DOTA-PEG4-Tz ([111In]1). The radiolabel stability
in plasma is decreasing significantly for approach A radiolabeled [111In]In-DPEG-TOPSi NPs already
after 1 h.
3.3. Ex Vivo Biodistribution
Biodistribution of [111In]In-DPEG-TOPSi and [111In]In-TOPSi particles was evaluated in order to
determine how much the dual PEGylation affected blood circulation time of the NPs. Biodistribution of
th [111I ]In-DOTA-PEG4-Tz ([111In]1) labeling agent was also determined as a control. All mice were
inject d with 100 µg of labeled particles (0.3–0.6 MBq) in 200 µL formulation solution intravenously
into tail vein. Blood samples from the contralat ral tail vein were taken at the selected time points
to follow the particle residence time in circulation. Mice w e sacrificed and the selected tissu s
wer c llected for gamma measu ments. The [111In]In-DPEG-TOPSi particles xhibited a typical
biodistribution patt rn f r NPs with high uptakes in the liver and spleen (44 ± 17%ID/g and 51 ±
5%ID/g at 1 h, respectively) (Figure 3A and Table S1). For the control particles, [111In]In-TOPSi, spleen
and liver upt kes were even higher (123 ± 10%ID/g and 69 ± 5%ID/g at 1h, respe tively). In addition,
there w s significantly higher lung uptake (18 ± 4%ID/g at 1 h) when compared to t e dual-PEGylated
particles. T lung accumul tion is typical for particles with increasing size, but also surface chemistry
of nanoparticles may also influen e the ccumulation. [111In]In-DOTA-PEG4-Tz ([111In]1) was fast
cleared through urinary system and no visible uptake in other organs was observed (Figure 3B).
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Blood radioactivity levels for [111In]In-DPEG-TOPSi were 15.8 ± 1.0%ID/g and 10.8 ± 1.7%ID/g
at 5 min and 15 min after injection (Figure 4). In particular, the value at 15 min is much higher than
typically observed for PSi nanoparticles [43,44]. For the control particles, the corresponding values
in blood at 5 min and 15 min were 14.9 ± 2.5 and 2.2 ± 1.3%ID/g. [111In]In-DOTA-PEG4-Tz labelling
agent showed still some activity in blood at 15 min (6.8 ± 2%ID/g), but was quickly washed from
organs as could be seen at 30 min in liver and spleen (1.4 ± 0.3%ID/g and 0.4 ± 0.3%ID/g, respectively
vs. 44 ± 17%ID/g and 51 ± 5%ID/g in liver and spleen for [111In]In-DPEG-TOPSi at 1 h). Despite
the improved blood residence time of [111In]In-DPEG-TOPSi NPs in the circulation, the 4T1 tumor
uptake was only 0.2 ± 0.1%ID/g at 1 h and improving only slightly to 0.3 ± 0.2%ID/g at 24 h time point
indicating low EPR effect (Figures S2 and S3). This is most probably due the relatively large size of
the particles (226 ± 3 nm) compared to what has been reported optimal for the EPR facilitated tumor
accumulation [45].
Figure 4. Quantification of resident time in blood for [111In]In-DPEG-TOPSi, [111In]In-TOPSi and
[111In]1 in Balb/c mice (n= 4) at 5 min, 15 min 30 min and 1 h after intravenous administration. Unpaired
t-test was used to assess the statistical significance of the difference in the of the two particle types in
blood, ** p > 0.0021.
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3.4. SPECT/CT Imaging
[111In]In-DPEG-TOPSi particles (100 µg, 2–4 MBq) were administered intravenously via the tail
vein and the animals were imaged under isoflurane anesthesia at 30 min, 5 h, and 24 h after the
NP administration (Figure 5.). Major uptake was seen already after 30 min in the spleen and liver,
demonstrating the characteristic accumulation of non-targeted PSi NPs by the mononuclear phagocyte
system (MPS). Unfortunately, the tumor activities were too low to be clearly visualized from the
SPECT/CT images.
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points for [111In]In-DPEG-TOPSi particles at 4T1 bearing mice. Location of the tumor is indicated by a
cursor. Highest radioactivity levels were observed in liver and spleen.
3.5. Tumor Autoradiography
Autoradiographic analysis of the intratumoral radioactivity distribution was carried out for tumors
harvested and sectioned at 1 h, 4 h and 24 h after the [111In]In-DPEG-TOPSi administration. The tumor
sections were imaged by using a BeaQuant real-time autoradiography system. The sections were H&E
stained for facilitating the histological orientation of the autoradiography findings. Radioactivity in
tumor was heterogeneously distributed showing higher activity levels around the major blood vessels
and outer layers possible containing more leaky vasculature (Figure 6 and Figure S5). Less activity
was observed in the deeper layers with more solid tumor tissue. Radiolabeled [111In]In-DPEG-TOPSi
particles (226 ± 3 nm) mainly migrated into the tumor tissue surface but not further to the middle of
tumor, which may be due to the relatively large size of the investigated NPs.
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